ALK's Acarizax Meets Main Goal in China Allergy Trial
ALK said its Acarizax met the main goal in a late-stage allergy trial in China.
Story updates
01:34:35 PM UTC
SquawkNews
Inside InformationALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced positive topline results from the phase 3 bridging trial evaluating the efficacy and safety of its house dust mite (‘HDM’) sublingual immunotherapy (‘SLIT’) tablet, ACARIZAX®, in Chinese participants aged 12 - 65 years with…
01:35:25 PM UTC
SquawkNews
ALK reported its China Phase 3 bridging trial met the primary endpoint for ACARIZAX in HDM allergy, showing a 1.11 TCRS difference (19.1%) vs placebo, and a safety profile consistent with prior data. Results are expected to support a local regulatory filing with GenSci.Material DetailsContext by AI…